Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
November 16, 2020 07:02 ET
|
Fennec Pharmaceuticals Inc.
~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™ ~ ~ No Clinical Safety or Efficacy Issues...
Fennec Announces Issuance of U.S. Patent for PEDMARK™
September 21, 2020 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
August 12, 2020 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that Rosty Raykov, Chief Executive Officer of Fennec...
Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
August 11, 2020 06:03 ET
|
Fennec Pharmaceuticals Inc.
~ No Clinical Safety or Efficacy Issues Identified, and No Requirement for Further Clinical Data ~ ~ FDA Pre-Approval Inspection has Identified Deficiencies with the Facility of the Drug Product...
Fennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
August 05, 2020 06:00 ET
|
Fennec Pharmaceuticals Inc.
~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~~ Strong Financial Position with $38.7 million in cash and no debt ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE...
Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility
June 26, 2020 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., June 26, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a...
Fennec Announces Results of Annual Meeting
June 22, 2020 18:03 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., June 22, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...
Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update
May 14, 2020 06:00 ET
|
Fennec Pharmaceuticals Inc.
~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~~ Marketing Authorization Application (MAA) Validated by the EMA in February 2020 ~~ Strengthened its Financial Position Through...
Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
May 08, 2020 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., May 08, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
Fennec Announces Closing of Public Offering
May 05, 2020 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., May 05, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...